Mira Pharmaceuticals, INC.
At a glance
EmployeesNot reported
In business sinceNot reported
HeadquartersSunny Isles Beach, FL
SAM.gov UEIWKYGCA2LJJX4
MIRA Pharmaceuticals develops novel oral therapies for neurologic, inflammatory, and metabolic disease. The company's lead program, Ketamir-2, has completed Phase 1 testing for chemotherapy-induced peripheral neuropathy and holds an active IND with the FDA. The pipeline includes MIRA-55 in preclinical development for chronic inflammatory pain and SKNY-1 in pre-IND stage for obesity and nicotine addiction.
Summarized from the company’s own website
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Mira Pharmaceuticals, INC. | Sunny Isles Beach | FL | — | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.